FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology and specifically to obtaining factor VII (FVII) and factor Vila (FVIIa) albumin linked polypeptides, and can be used in medicine. A polypeptide, which is a FVII or FVIIa polypeptide is obtained in a recombinant manner, said peptide being linked with albumins through a glycerine-serine peptide linker of a special structure, which separates part associated with FVII or FVIIa from the albumin part, wherein the FVII or FVIIa polypeptide lies on the N-end of the fused protein. The linked polypeptide or vector structure, which contains its coding nucleic acid, is used as a medicinal agent for treating or preventing blood-clotting disorders.
EFFECT: invention enables to obtain a protein with FVII or FVIIa biological activity and longer functional half-time in plasma in vitro compared to non-linked FVII or FVIIa.
12 cl, 4 dwg, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED VITAMIN K DEPENDENT POLYPEPTIDES | 2005 |
|
RU2396347C2 |
| DERIVATIVES OF BLOOD COAGULATION FACTORS VII AND VIIA, CONJUGATES AND COMPLEXES CONTAINING THEM AND THEIR APPLICATION | 2012 |
|
RU2620072C2 |
| NEW TISSUE FACTOR ANTIBODIES AS ANTICOAGULANTS | 2003 |
|
RU2345789C2 |
| FUSED PROTEIN, HAVING FACTOR VII ACTIVITY | 2011 |
|
RU2585231C2 |
| DERIVATIVES OF FACTOR OF VII BLOOD COAGULATION | 2002 |
|
RU2338752C2 |
| FACTOR VII CHIMERIC MOLECULES | 2010 |
|
RU2563231C2 |
| NEW THROMBOMODULINE FUSION PROTEINS PROVIDING DIRECTIONAL TRANSFER TO TISSUE FACTOR AS ANTICOAGULANTS | 2003 |
|
RU2320366C2 |
| POLYPEPTYDE OF HEMOSTASIS FACTOR VII, PRODUCTION AND APPLICATION | 2001 |
|
RU2326126C2 |
| FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
| POLYPEPTIDE OF VII HUMAN COAGULATION FACTOR, PRODUCTION AND APPLICATION | 2002 |
|
RU2325401C2 |
